GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
核心洞察
GRI Bio's GRI-0621, an oral RARβ/γ (搜索)-selective agonist, received FDA Orphan Drug Designation for idiopathic pulmonary fibrosis (搜索), a progressive and fatal lung disease.
The designation provides potential seven-year U.S. market exclusivity, tax credits for clinical development, and waiver of certain FDA application fees.
The regulatory milestone was supported by a Phase 2a trial in 35 IPF patients where GRI-0621 met all primary, secondary, and exploratory endpoints.
GRI Bio, Inc. (搜索) (NASDAQ: GRI), a biotechnology company focused on inflammatory, fibrotic and autoimmune diseases, announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to GRI-0621 for the treatment of idiopathic pulmonary fibrosis (搜索), a progressive, irreversible and ultimately fatal lung disease affecting tens of thousands of patients in the United States.
"Receiving FDA Orphan Drug Designation for GRI-0621 in IPF is an important validation of our development strategy and highlights the urgent need for innovative therapies capable of altering the course of this devastating disease," said Marc Hertz, Ph.D., Chief Executive Officer of GRI Bio. "We believe GRI-0621's differentiated mechanism of action has the potential to address key drivers of inflammation and fibrosis, and this designation strengthens our ability to advance the program efficiently while creating significant long-term value for patients and shareholders."
Orphan Drug Designation Benefits
Orphan Drug Designation is granted to therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States. The designation confers several important development and commercialization benefits, including potential eligibility for seven years of U.S. market exclusivity upon approval, tax credits related to qualified clinical development expenses, waiver of certain FDA application fees, and enhanced regulatory engagement with the FDA throughout development.
The designation represents a significant regulatory achievement for GRI-0621 and reinforces the growing recognition of the drug's potential to address significant unmet medical needs in fibrotic diseases.
GRI-0621 Mechanism and Clinical Data
GRI-0621 is a once-daily oral RARβ/γ (搜索)-selective investigational therapy designed to modulate pathways involved in inflammation and fibrosis in IPF. Emerging scientific evidence increasingly supports the role of immune dysfunction in driving fibrosis, creating opportunities for novel therapeutic approaches beyond current standards of care.
The drug candidate was evaluated in a randomized, double-blind, placebo-controlled Phase 2a trial (GRI-0621-IPF-02; NCT06331624) in 35 patients with IPF, approximately 80% of whom were on background standard-of-care antifibrotics. The trial met its primary, secondary and exploratory endpoints, with continued analyses and positive outcomes supporting previously reported findings.
The IPF Treatment Landscape
Idiopathic pulmonary fibrosis (搜索) remains one of the most challenging pulmonary diseases, characterized by progressive scarring of lung tissue that leads to declining lung function and premature mortality. The disease leads to declining respiratory function, reduced quality of life, and shortened survival. Despite currently approved therapies, patients continue to face poor long-term outcomes, underscoring the need for additional treatment options capable of improving outcomes and slowing disease progression.
"We are committed to advancing GRI-0621 with urgency and discipline," added Dr. Hertz. "This designation further strengthens our regulatory foundation and supports our mission of delivering innovative therapies for patients with severe diseases while building a biotechnology company positioned for sustainable long-term growth."
The Orphan Drug Designation adds another catalyst to GRI Bio's broader strategy of advancing innovative therapies for diseases driven by immune dysregulation and fibrosis. The Company continues to execute on key development objectives while exploring opportunities to maximize the value of its proprietary platform.